{"id":"W2774483419","doi":"10.1158/2159-8290.cd-17-1119","title":"First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Medicine; Adverse effect; Nausea; Neuroblastoma RAS viral oncogene homolog; Cohort; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Cancer; Pharmacokinetics; MEK inhibitor; Oncology; Gastroenterology; MAPK/ERK pathway; Pharmacology; Clinical trial; Phases of clinical research; Kinase; Colorectal cancer; KRAS","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001155503,0.0001680101,0.0002547683,0.00005304682,0.00007669353,0.00003957673,0.0001380122,0.00007598925,0.000002243331],"category_scores_gemma":[0.00008071801,0.0001374561,0.00002887987,0.00004927182,0.00007591431,0.00004792871,0.0001128104,0.00007771653,4.521464e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000336349,"about_ca_system_score_gemma":0.00009725372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002037705,"about_ca_topic_score_gemma":0.001968547,"domain_scores_codex":[0.9988205,0.00003368854,0.0003483804,0.0004353083,0.0001553776,0.0002067477],"domain_scores_gemma":[0.9991203,0.000009965534,0.0002842321,0.0004768349,0.00005369795,0.00005497839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01245333,0.002048809,0.6263078,0.0001345477,0.00005113744,0.00003422829,0.001013987,0.0003631028,0.3484898,0.00000810243,0.0001100311,0.008985083],"study_design_scores_gemma":[0.02126631,0.002807692,0.8086477,0.0003999554,0.00001998333,7.107826e-7,0.000317183,0.0001303006,0.1658493,0.00001527935,0.0002779361,0.0002676592],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986793,0.0001352964,0.0000242673,0.00004088403,0.0001575628,0.0006388788,0.0001783482,0.000003671636,0.0001417546],"genre_scores_gemma":[0.99954,0.00006314118,0.00002863531,0.0000210609,0.00008221703,0.00008258001,0.00009075343,0.00001804945,0.00007360236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1826405,"threshold_uncertainty_score":0.5605297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01034731323142016,"score_gpt":0.2735128579624377,"score_spread":0.2631655447310176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}